{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:30:24Z","timestamp":1784629824862,"version":"3.55.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T00:00:00Z","timestamp":1596585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["\u041e-06-17"],"award-info":[{"award-number":["\u041e-06-17"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2020.01185","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T05:26:57Z","timestamp":1596605217000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["DPP-4 Inhibitors in the Prevention\/Treatment of Pulmonary Fibrosis, Heart and Kidney Injury Caused by COVID-19\u2014A Therapeutic Approach of Choice in Type 2 Diabetic Patients?"],"prefix":"10.3389","volume":"11","author":[{"given":"Andrija","family":"Smelcerovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Kocic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihajlo","family":"Gajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Tomovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vukica","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dobrila","family":"Stankovic-Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko","family":"Anderluh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2019.00071","article-title":"Multi-target-directed ligands (MTDL) as challenging research tools in drug discovery: From design to pharmacological evaluation","volume":"7","author":"Alcaro","year":"2019","journal-title":"Front. Chem."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.pharmthera.2016.07.009","article-title":"Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: potential impact of dipeptidyl peptidase-4 inhibitors","volume":"167","author":"Anderluh","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2019.05.007","article-title":"DPP-4 inhibition: \u0410 novel therapeutic approach to the treatment of pulmonary hypertension","volume":"201","author":"Anderluh","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.13052","article-title":"COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity","author":"Bassendine","year":"2020","journal-title":"J. Diabetes"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12955-019-1165-2","article-title":"Quality of life reported by survivors after hospitalization for Middle East respiratory syndrome (MERS)","volume":"17","author":"Batawi","year":"2019","journal-title":"Health Qual. Life Outc."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.05.006","article-title":"Diabetes and COVID-19","author":"Bouhanick","year":"2020","journal-title":"Therapie."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/JCMA.0000000000000338","article-title":"Role of Dipeptidyl Peptidase 4 Inhibitors in Diabetic Patients with Coronavirus-19 Infection","author":"Chen","year":"2020","journal-title":"J. Chin. Med. Assoc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/dc20-0660","article-title":"Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication","volume":"47","author":"Chen","year":"2020","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108216","article-title":"Is DPP4 inhibition a comrade or adversary in COVID-19 infection","volume":"164","author":"Dalan","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00080","article-title":"Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes","volume":"10","author":"Deacon","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnaa011","article-title":"Coronavirus Infections and Type 2 Diabetes \u2013 Shared Pathways with Therapeutic Implications","volume":"41","author":"Drucker","year":"2020","journal-title":"Endocr. Rev."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14097","article-title":"Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study","author":"Fadini","year":"2020","journal-title":"Diabetes Obes. Metab."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108125","article-title":"COVID-19 and diabetes: Can DPP4 inhibition play a role","volume":"162","author":"Iacobellis","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108163","article-title":"Letter to the Editor in response to the article \u201cCOVID-19 and diabetes: Can DPP4 inhibition play a role","volume":"163","author":"Kokic Males","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1286","article-title":"Potential effects of coronaviruses on the cardiovascular system: a review","author":"Madjid","year":"2020","journal-title":"JAMA Cardiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/j.1440-1843.2010.01720.x","article-title":"The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status","volume":"15","author":"Ngai","year":"2010","journal-title":"Respirology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.46234\/ccdcw2020.032","article-title":"The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) in China","volume":"2","year":"2020","journal-title":"China CDC Weekly"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2835","DOI":"10.17771\/PUCRio.escrita.46615","article-title":"Editorial \u2013 COVID-19 pandemic: is it time to learn about DPP-4\/CD26","volume":"8","author":"Pinheiro","year":"2020","journal-title":"CellR4"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword","volume":"395","author":"Ritchie","year":"2020","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"Russel","year":"2020","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1473-3099(20)30086-4","article-title":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study","volume":"20","author":"Shi","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3330","article-title":"DPP4 inhibition: preventing SARS-CoV-2 infection and\/or progression of COVID-19","author":"Strollo","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/med.21513","article-title":"Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection","volume":"39","author":"Tomovic","year":"2019","journal-title":"Med. Res. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/22221751.2020.1739565","article-title":"Emerging COVID-19 coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26","volume":"9","author":"Vankadari","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China","volume":"323","author":"Wang","year":"2020","journal-title":"JAMA"},{"key":"B28","unstructured":"Coronavirus disease 2019 (COVID-19) Situation report \u2013 1742020"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41374-018-0080-1","article-title":"Dipeptidyl peptidase IV (DPP-4) inhibition alleviates pulmonary arterial remodeling in experimental pulmonary hypertension","volume":"98","author":"Xu","year":"2018","journal-title":"Lab. Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01185\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T05:27:00Z","timestamp":1596605220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2020.01185\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,5]]},"references-count":30,"alternative-id":["10.3389\/fphar.2020.01185"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2020.01185","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,5]]},"article-number":"1185"}}